Matches in Nanopublications for { ?s ?p "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_assertion description "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_provenance.
- NP492860.RAB4eFg4esdjA6H8LWYIODH-DzzJtvXH2xoZABf8AZDuA130_assertion description "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492860.RAB4eFg4esdjA6H8LWYIODH-DzzJtvXH2xoZABf8AZDuA130_provenance.
- NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_assertion description "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_provenance.